Ignite Creation Date:
2025-12-24 @ 1:17 PM
Ignite Modification Date:
2026-04-23 @ 6:50 AM
Study NCT ID:
NCT00539695
Status:
COMPLETED
Last Update Posted:
2018-05-04
First Post:
2007-10-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
Sponsor:
Baylor College of Medicine
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Acute Lymphoblastic Leukemia | View |
| None | ALL | View |
| None | Acute Myelogenous Leukemia | View |
| None | AML | View |
| None | Chronic Myelogenous Leukemia | View |
| None | Myelodysplastic Syndrome | View |
| None | Myeloproliferative Disorder | View |
| None | Hodgkin Lymphoma | View |
| None | Non-Hodgkin Lymphoma | View |
| None | Non-malignant Diseases Requiring Allogeneic HSCT | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Stem Cell transplant | View |
| None | Graft verus host disease | View |
| None | IL-2 | View |
| None | acute lymphoblastic leukemia | View |
| None | ALL | View |
| None | acute myelogenous leukemia | View |
| None | AML | View |
| None | chronic myelogenous leukemia | View |
| None | myelodysplastic syndrome | View |
| None | myeloproliferative disorder | View |
| None | Hodgkin lymphoma | View |
| None | non-Hodgkin lymphoma | View |
| None | non-malignant diseases requiring allogeneic HSCT | View |